Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 831 results for "novartis ag"

Amgen, Inc. Fails To Block Novartis AG (ADR) From Launching Biosimilar
Bidness Etc

Amgen, Inc. Fails To Block Novartis AG (ADR) From Launching Bi...

A federal appeals court on Wednesday rejected Amgen Inc.'s ( NASDAQ:AMGN ) request for a temporary injunction to block Novartis AG (ADR) ( NYSE:NVS ) from launching a biosimilar version of Amgen's blockbuster drug, Neupogen, in the US. According ... Bidness Etc, 5 hours ago

18 images for novartis ag

PR inside, 1 week ago
WallStreetScope.com, 1 week ago
FOXBusiness.com, 1 day ago
Bidness Etc, 5 hours ago
Medagadget.com, 2 weeks ago
Live Trading News, 1 month ago
Livemint.com, 1 week ago
Bidness Etc, 1 week ago
Bidness Etc, 1 week ago
Irish Times, 1 month ago
LocalNews7.com

Some leukemia patients see durable results from Novartis therapy

Some leukemia patients who had exhausted other treatment options have no trace of the disease more than four years after being treated with an experimental type of therapy called CAR T cells in a small pilot study at the University of Pennsylvania. ...
 LocalNews7.com5 hours ago Some leukemia patients see durable...  DailyNews724.com41 minutes ago
Channel NewsAsia

Amgen cannot stop imminent sale of Neupogen copycat: US appeals court

REUTERS: A U.S. appeals court has cleared the way for Novartis AG to launch the first biosimilar drug in the United States as it declined on Wednesday to stop the sale of the company's copycat version of Amgen Inc's blockbuster cancer drug Neupogen.
 Channel NewsAsia1 day ago Novartis can sell biosimilar of Amgen's filgrastim in September, court rules  Pharmacist.com1 month ago
[x]  
FOXBusiness.com

Amgen to Help Develop Novartis's Pipeline of Alzheimer's Drugs

(Reuters) Novartis AG will share the risks and rewards as Amgen Inc. will help develop its pipeline of experimental Alzheimer's disease drugs, in a move that is becoming increasingly commonplace among drug makers eager to address the ...
 FOXBusiness.com1 day ago
Moneycontrol.com

Novartis India gets FIPB nod to sell OTC biz to GSK CPL

NEW DELHI: Novartis India today said it has received FIPB approval to sell its OTC division to GlaxoSmithKline Consumer Pvt Ltd (GSK CPL) and will now proceed to complete the transaction. The Foreign Investment Promotion Board (FIPB) has approved the proposal ...
 Economic Times6 days ago
Bidness Etc

Novartis AG (ADR) (NVS) Stock Update: Decline Driven By Forex Headwinds

Novartis AG (ADR) ( NYSE:NVS ) stock has registered a decline of 6.06% over the past three months, aided in large part by the global market chaos that's bogging down the entire healthcare sector's stock performance. The company stock has added 4.67% ...
 Bidness Etc1 week ago How Will Novartis AG Fare After Acquisition of MS Drug From GlaxoSmithKline plc  Bidness Etc1 week ago Novartis AG (ADR) (NYSE:NVS) To Spend $1B On GlaxoSmithKline plc (ADR) (NYSE:GSK) MS Drug  WallStreetScope.com1 week ago GlaxoSmithKline plc Deal Unlikely To Help Novartis AG Top Oncology Sales  Bidness Etc2 weeks ago
[x]  
EuroInvestor

Novartis continues commitment to go the last mile in effort to eliminate leprosy

Novartis International AG / . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement. The digital press release with multimedia content can be accessed here: ...
 EuroInvestor6 days ago Novartis to buy rights to Glaxo MS drug for up to $1 billion  Livemint.com1 week ago Novartis To Buy Rest Of Rights To GSK's Auto-immune Drug Ofatumumab For $1 Bln  RTTNews.com1 week ago Novartis Gets Multiple Sclerosis Drug from GlaxoSmithKline  Mergers & Acquisitions1 week ago
[x]  

Novartis AG (NVS) Showing Support Near $101.95

Option-trade picking algorithms patented by MarketIntelligenceCenter.com found a trading opportunity with Novartis AG (http://www.marketintelligencecenter.com/symbol/NVS"NVS) that should provide a 3.54% return in just 168 days. Sell one Jan. '16 ...
 Individual.com1 month ago Novartis AG (NVS) Showing Bearish Technicals With Resistance At $104.09  Individual.com1 month ago Novartis AG (NVS) Trading Near $102.17 Support Level  Individual.com1 month ago Novartis AG (NVS) Showing Bullish Technicals With Support At $105.11  Individual.com1 month ago

Potential Novartis AG (NVS) Trade Has 6.65% Downside Protection

A covered call identified by MarketIntelligececenter.com's patented algorithm on Novartis AG (http://www.marketintelligencecenter.com/symbol/NVS"NVS) could yield about 3.25% (7.19% annualized, for comparison purposes only) in 165 days. Pair a long ...
 Individual.com1 month ago Potential Novartis AG (NVS) Trade Targets 3.53% Return  Individual.com1 month ago
DailyNews724.com

FDA approves Odomza from Novartis for increasingly common skin cancer, basal cell carcinoma

EAST RUTHERFORD, N.J. A new drug for advanced basal cell carcinoma, an increasingly common cancer in the skin's top layer, has won Food and Drug Administration approval. Odomza (pronounced ah-DOMM'-zoh) was approved for patients whose cancer ...
 FOXBusiness.com1 month ago FDA OK's Odomza from Novartis for common skin cancer type  Investor's Business Daily1 month ago BRIEF-Novartis says FDA approves Odomzo to treat form of skin cancer  Reuters1 month ago FDA approves Novartis's advanced skin cancer drug  Sharenet1 month ago
[x]  
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - novartis ag
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less